The Community Research Advisors Group (CRAG) celebrates both the findings and the methodology of Study 35, a phase I/II clinical trial of the tuberculosis (TB) preventive treatment regimen known as 3HP in children.
Treatment Action Group (TAG) is deeply concerned by the reported decrease in domestic funding for tuberculosis (TB) services announced today in the World Health Organization's 2024 Global Tuberculosis Report.
Treatment Action Group (TAG) supports the World Health Organization (WHO) in declaring the renewed outbreak of mpox a public health emergency of international concern.
Microarray patches (MAPs) are arrays of microneedles that stick to your skin like a bandage, offering a noninvasive mechanism for drug administration.
In response to disheartening news of the proposed $5.3 million cut in HIV/AIDS funding by the Adams administration, we at Treatment Action Group (TAG) express our resolute opposition, in solidarity with our partner organizations that would be harmed by the egregious, unconscionable cuts to HIV services and programs in New York City.
Rifapentine, an off-patent drug that's been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.
TAG hosted this May 31 webinar on the growing pipeline of microarray patches (MAPs) for various infectious diseases treatment and immunization.
On May 7 and 21, TAG celebrated Pride season by hosting for an essential webinar that addressed the unique health concerns of the LGBTQ+ community, focusing on engaging LGBTQ patients.
On March 27, 2024, the 1/4/6x24 Campaign and the Stop TB Partnership co-hosted a webinar to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments.
Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6x24 Campaign coalition has found.